Johnson & Johnson Reaches $5.5B Settlement [titlebase] Over Talc Claims, Bringing Decade-Long Litigation to an End

floriparesort.com – 28 July 2026 | Johnson & Johnson Reaches $5.5B settlement [titlebase] in a landmark deal that could finally bring an end to the decade-long litigation over its talc-based baby powder and other talc products. The proposed settlement, announced on July 27, covers about 76,000 pending ovarian cancer claims in US federal and state courts. However, it will only take effect if at least 95 per cent of eligible claimants agree to participate.

The healthcare giant continues to deny that its talc products are unsafe or contained asbestos, saying the agreement is intended to end years of litigation while allowing the company to focus on its healthcare business. Johnson & Johnson Reaches $5.5B settlement [titlebase] marks a major turning point in the long-running litigation over its talc-based baby powder.

The company stopped selling talc-based baby powder in the US in 2020, switching to a cornstarch product. The litigation resumed in March 2025, after being put on hold for more than three years during J&J’s repeated failed attempts to resolve the lawsuits through a shell company’s bankruptcy.

Johnson & Johnson Reaches $5.5B settlement [titlebase] is a significant development in the ongoing saga, with the company committing to pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause ovarian cancer. The deal must be accepted by 95% of the ovarian cancer claimants in state or federal court before it becomes final.

Erik Haas, J&J’s vice president of litigation, described the lawsuits as ‘meritless’ and said the settlement would allow the company to put the long-running litigation behind it. ‘While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,’ Haas said.

Johnson & Johnson Reaches $5.5B settlement [titlebase] is expected to bring closure to the thousands of claimants who have been seeking justice for years. The settlement assigns specific values to qualifying ovarian cancer claims but does not cap J&J’s total payout. Chris Seeger, an attorney who represents about 2,500 clients with talc claims and helped negotiate the agreement, said J&J could ultimately pay $7 billion or more.

In conclusion, Johnson & Johnson Reaches $5.5B settlement [titlebase] is a significant milestone in the long-running talc litigation. The proposed settlement brings an end to the decade-long litigation, allowing the company to focus on its healthcare business while providing closure to the thousands of claimants. Johnson & Johnson Reaches $5.5B settlement [titlebase] is a landmark deal that could finally bring an end to the saga, and the company can now move forward with its mission to develop medicines and devices that save lives.

Baca Juga

Ebola Travel Restrictions [Titlebase] Imposed Amid Outbreak, World Cup Concerns

Baca Juga

Fifth Person Dies in NYC Legionnaires’ Outbreak as City Battles to Contain Crisis

Baca Juga

FDA OKs 1st mRNA Flu Shot, A New Era in Influenza Vaccination Begins with Moderna’s mFLUSIVA